Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Exp Hematol ; 41(2): 189-97, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23085465

RESUMO

DNA methyltransferase inhibitors (DNMTIs), including decitabine (DAC) and azacitidine (AZA), have recently been highlighted for the treatment of high-risk myelodysplastic syndrome (MDS); however, their action mechanisms have not been clearly defined. Therefore, we investigated the effects of DNMTIs on MDS-derived cell lines in vitro. An MDS-derived cell line MDS92 and its blastic subline MDS-L and HL-60 were used. All three cell lines were sensitive to DNMTIs, but MDS-L was the most susceptible. DAC-induced cell death in MDS-L was preceded by DNA damage-induced G2 arrest via a p53-independent pathway. AZA did not influence the pattern of cell cycle, although it induced DNA damage response. The IC(50) of DAC or AZA on MDS-L cells was associated with the dose inducing the maximal hypomethylation in long interspersed nuclear elements-1 (LINE-1) methylation assay. AZA suppressed the level of methylation in a time-dependent manner (days 4, 7, and 10), whereas DAC maintained the level of methylation from day 4 to 11. The protein expression of DNMT1 and DNMT3a decreased with the suppression of growth and methylation. We conclude that this study provides in vitro models for understanding the effects of DNMTIs on cell growth and gene regulation, including differences in the possible action mechanism of DAC and AZA.


Assuntos
Azacitidina/análogos & derivados , Azacitidina/farmacologia , DNA (Citosina-5-)-Metiltransferases/antagonistas & inibidores , Inibidores Enzimáticos/farmacologia , Síndromes Mielodisplásicas/patologia , Ciclo Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular/efeitos dos fármacos , DNA (Citosina-5-)-Metiltransferase 1 , Dano ao DNA , Metilação de DNA/efeitos dos fármacos , Decitabina , Relação Dose-Resposta a Droga , Perfilação da Expressão Gênica , Células HL-60/efeitos dos fármacos , Humanos , Técnicas In Vitro , Concentração Inibidora 50
2.
Leuk Lymphoma ; 49(9): 1784-91, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18661406

RESUMO

The objective of this study was to validate the recently revised 2008 WHO diagnostic criteria of myeloproliferative neoplasms (MPN) together with the analysis of correlation of JAK2 (Janus kinase 2)-V617F mutant allele burden with clinical/laboratory findings on each patient. We made a diagnosis of 75 suspected MPN patients based on both diagnostic criteria of the 2001 WHO classification and the revised 2008 WHO classification, and found that both criteria show a quite similar diagnostic power except for two patients (idiopathic erythrocytosis (IE) and thrombocytosis) who were diagnosed as essential thrombocythemia by the 2008 WHO criteria. From JAK2-V617F analysis, hemoglobin and hematocrit values were significantly higher and platelet count was lower in JAK2-V617F high allele burden group than JAK2-V617F middle allele burden group. Mutant allele burden of polycythemia vera (PV) group was higher than that of essential thrombocythemia group. Therefore, the amount of mutant allele seemed to define the disease phenotypes. We further found a PV case presenting a rare type of JAK2-exon12 mutation. In contrast, IE presented a good prognosis unlike MPN. Hereafter, the 2008 WHO criteria with JAK2 gene analysis are useful for precise diagnosis of MPN and the patients with erythrocytosis.


Assuntos
Transtornos Mieloproliferativos/diagnóstico , Guias de Prática Clínica como Assunto/normas , Organização Mundial da Saúde , Adulto , Idoso , Diagnóstico , Testes Hematológicos , Humanos , Janus Quinase 2/genética , Pessoa de Meia-Idade , Mutação , Transtornos Mieloproliferativos/classificação , Policitemia , Policitemia Vera , Trombocitemia Essencial , Trombocitose
3.
Cytometry B Clin Cytom ; 74(2): 104-9, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18044723

RESUMO

BACKGROUND: Megaloblastic anemias are characterized by several hematopoietic cells with dysplastic nuclear morphology. The analyses of DNA ploidy and cell cycle of these cells are important to understand the property of such diseases. METHODS: As laser scanning cytometry (LSC) is a useful tool to evaluate the morphology of the cells fixed on the slide glass together with the quantitative analysis of the fluorescence information of each cell by rapid scanning of the specimens, the authors examined the DNA ploidy and cell cycle of six cases with megaloblastic anemia using LSC. RESULTS: Giant neutrophilic series such as giant metamyelocytes and giant band cells were found to have extraordinarily higher DNA ploidy, while hypersegmented neutrophils represented the normal diploid pattern like normal neutrophils. As to megaloblasts, cell cycle analysis showed that the proportion of the cells in S phase was increased as compared with the case of normal erythroblasts. CONCLUSIONS: The present study clearly demonstrates the abnormal aspects of the hematopoietic cells with megaloblastic anemia from the viewpoint of the DNA ploidy and cell cycle analyzed by the use of LSC.


Assuntos
Anemia Megaloblástica/diagnóstico , Anemia Megaloblástica/genética , Células da Medula Óssea/patologia , Ciclo Celular/genética , Aberrações Cromossômicas , Citometria de Varredura a Laser/métodos , Ploidias , Anemia Megaloblástica/sangue , Núcleo Celular/patologia , DNA/genética , Células Gigantes/patologia , Células Precursoras de Granulócitos/patologia , Células HL-60 , Células-Tronco Hematopoéticas/patologia , Humanos , Megaloblastos/patologia , Neutrófilos/patologia , Fase S/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...